肿瘤药物敏感性预测模型及其在膀胱癌中的应用

应毅蝶; 曾蜀雄; 许传亮

doi:10.13201/j.issn.1001-1420.2020.03.015

肿瘤药物敏感性预测模型及其在膀胱癌中的应用

- 海军军医大学附属长海医院泌尿外科(上海, 200433)
基金项目:
国家自然科学基金项目(No:81802515,81972391,81772720,81572509)

上海市青年科技英才扬帆计划(No:18YF1422700)

第二军医大学青年启动基金(No:2017QN11)

详细信息

通讯作者: 许传亮,E-mail:chuanliang_xu@126.com

中图分类号: R737.14

收稿日期: 2019-05-08

Cancer models to predict drug response and its application in bladder cancer research

- Department of Urology, Changhai Hospital of Naval Medical University, Shanghai, 200433, China

More Information

Corresponding author: XU Chuanliang, E-mail: chuanliang_xu@126.com

Received Date: 08 May 2019

摘要

摘要: 目前,在精准医疗背景下,需要研究不同抗肿瘤药物对患者的治疗效果,并将最敏感的药物作用于患者,从而实现肿瘤的个体化治疗。而药物敏感性的研究依赖于高度还原患者肿瘤特征的肿瘤模型。目前,常见的肿瘤模型包括致癌物动物模型、移植物动物模型、肿瘤细胞株培养、3D培养模型、类器官、转基因动物模型、微流体器官芯片模型,这些药敏性预测模型已经越来越多地用于肿瘤研究与治疗,并且取得了一定的效果。在膀胱癌领域这些模型应用仍较少,因此亟需将这些模型引入膀胱癌的诊治中。本综述将介绍多种药敏性预测模型基本特点,在临床研究中的应用及其前景。
- 膀胱癌 /
- 精准医疗 /
- 个体化治疗 /
- 肿瘤模型
Abstract: Nowadays,in the context of precision medicine,the treatment of cancer requires analyzing the responses of each patient to different anti-cancer drugs,and then administer the most effective drug to the patient to achieve individualized medicine.This process requires cancer models which faithfully recapitulate the characteristics of the tumor.To date,models of cancer usually include:carcinogen-based animal models,engraftment models,cancer cell-line models,3 Dculture models,organoids,genetically-engineered mouse models,microfluidic organ-on-a-chip.These models are being applied more frequently in cancer research and treatment,and have yielded certain results.However,relatively few models of bladder cancer have been described.Thus,it's urgent to introduce these models into the diagnosis and treatment of bladder cancer.This review focuses on the basic characteristics of various models which predict drug response,the application of these models in clinical research and its future prospect.
- bladder cancer /
- precision medicine /
- individualized medicine /
- cancer model

HTML全文

参考文献(69)

[1]	Kobayashi T,Owczarek TB,McKiernan JM,et al.Modelling bladder cancer in mice:opportunities and challenges[J].Nat Rev Cancer,2015,15(1):42-54.
[2]	Kamat AM,Hahn NM,Efstathiou JA,et al.Bladder cancer[J].Lancet,2016,388(10061):2796-2810.
[3]	Nardella C,Lunardi A,Patnaik A,et al.The APL paradigm and the"co-clinical trial"project[J].Cancer Discov,2011,1(2):108-116.
[4]	Juffs HG,Moore MJ,Tannock IF.The role of systemic chemotherapy in the management of muscle-invasive bladder cancer[J].Lancet Oncol,2002,3(12):738-747.
[5]	Sternberg Cora N,Yagoda A,Scher Howard I,et al.Preliminary Results of M-VAC(Methotrexate,Vinblastine,Doxorubicin and Cisplatin)for Transitional Cell Carcinoma of the Urothelium[J].J Urol,1985,133(3):403-407.
[6]	Loehrer PJ,Einhorn LH,Elson PJ,et al.A randomized comparison of cisplatin alone or in combination with methotrexate,vinblastine,and doxorubicin in patients with metastatic urothelial carcinoma:a cooperative group study[J].J Clin Oncol,1992,10(7):1066-1073.
[7]	von der Maase H,Hansen SW,Roberts JT,et al.Gemcitabine and cisplatin versus methotrexate,vinblastine,doxorubicin,and cisplatin in advanced or metastatic bladder cancer:results of a large,randomized,multinational,multicenter,phase III study[J].J Clin Oncol,2000,18(17):3068-3077.
[8]	Alfred Witjes J,Lebret T,Compérat EM,et al.Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer[J].Eur Urol,2017,71(3):462-475.
[9]	Bellmunt J,de Wit R,Vaughn DJ,et al.Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma[J].N Engl J Med,2017,376(11):1015-1026.
[10]	Rosenberg JE,Hoffman-Censits J,Powles T,et al.Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy:a single-arm,multicentre,phase 2trial[J].Lancet,2016,387(10031):1909-1920.
[11]	Sharma P,Callahan MK,Bono P,et al.Nivolumab monotherapy in recurrent metastatic urothelial carcinoma(CheckMate 032):a multicentre,open-label,twostage,multi-arm,phase 1/2 trial[J].Lancet Oncol,2016,17(11):1590-1598.
[12]	Massard C,Gordon MS,Sharma S,et al.Safety and Efficacy of Durvalumab(MEDI4736),an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor,in Patients With Advanced Urothelial Bladder Cancer[J].JClin Oncol,2016,34(26):3119-3125.
[13]	Apolo AB,Infante JR,Balmanoukian A,et al.Avelumab,an Anti-Programmed Death-Ligand 1 Antibody,In Patients With Refractory Metastatic Urothelial Carcinoma:Results From a Multicenter,Phase Ib Study[J].JClin Oncol,2017,35(19):2117-2124.
[14]	Patel MR,Ellerton J,Infante JR,et al.Avelumab in metastatic urothelial carcinoma after platinum failure(JAVELIN Solid Tumor):pooled results from two expansion cohorts of an open-label,phase 1trial[J].Lancet Oncol,2018,19(1):51-64.
[15]	Lattanzi M,Balar AV.Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma[J].Curr Oncol Rep,2019,21(3):24.
[16]	黄传书,蒋国松,黄超.膀胱癌治疗基础及临床转化研究的前沿和热点[J].临床泌尿外科杂志,2017,32(10):735-740.
[17]	Alfred Witjes J,Lebret T,Compérat EM,et al.Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer[J].Eur Urol,2017,71(3):462-475.
[18]	Alifrangis C,McGovern U,Freeman A,et al.Molecular and histopathology directed therapy for advanced bladder cancer[J].Nat Rev Urol,2019,16(8):465-483.
[19]	Milowsky MI,Iyer G,Regazzi AM,et al.Phase II study of everolimus in metastatic urothelial cancer[J].BJUInt,2013,112(4):462-470.
[20]	Pal SK,Rosenberg JE,Hoffman-Censits JH,et al.Efficacy of BGJ398,a Fibroblast Growth Factor Receptor 1-3 Inhibitor,in Patients with Previously Treated Advanced Urothelial Carcinoma with Alterations[J].Cancer Discov,2018,8(7):812-821.
[21]	Loriot Y,Necchi A,Park SH,et al.Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma[J].NEngl J Med,2019,381(4):338-348.
[22]	Montazeri K,Bellmunt J.Erdafitinib for the treatment of metastatic bladder cancer[J].Expert Rev Clin Pharmacol,2020,13(1):1-6.
[23]	Lee JK,Liu Z,Sa JK,et al.Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy[J].Nat Genet,2018,50(10):1399-1411.
[24]	Drost J,Clevers H.Organoids in cancer research[J].Nat Rev Cancer,2018,18(7):407-418.
[25]	Weeber F,van de Wetering M,Hoogstraat M,et al.Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases[J].Proc Natl Acad Sci U S A,2015,112(43):13308-13311.
[26]	Crespo M,Vilar E,Tsai SY,et al.Colonic organoids derived from human induced pluripotent stem cells for modeling colorectal cancer and drug testing[J].Nat Med,2017,23(7):878-884.
[27]	Lee SH,Hu W,Matulay JT,et al.Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer[J].Cell,2018,173(2):515-528.
[28]	Pauli C,Hopkins BD,Prandi D,et al.Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine[J].Cancer Discov,2017,7(5):462-477.
[29]	Gao D,Chen Y.Organoid development in cancer genome discovery[J].Curr Opin Genet Dev,2015,30:42-48.
[30]	Boj SF,Hwang CI,Baker LA,et al.Organoid models of human and mouse ductal pancreatic cancer[J].Cell,2015,160(1-2):324-338.
[31]	Sachs N,de Ligt J,Kopper O,et al.A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity[J].Cell,2018,172(1-2):373-386.
[32]	Vlachogiannis G,Hedayat S,Vatsiou A,et al.Patientderived organoids model treatment response of metastatic gastrointestinal cancers[J].Science,2018,359(6378):920-926.
[33]	Selimovic S,Dokmeci MR,Khademhosseini A.Organson-a-chip for drug discovery[J].Curr Opin Pharmacol,2013,13(5):829-833.
[34]	Horvath P,Aulner N,Bickle M,et al.Screening out irrelevant cell-based models of disease[J].Nat Rev Drug Discov,2016,15(11):751-769.
[35]	Bhatia SN,Ingber DE.Microfluidic organs-on-chips[J].Nat Biotechnol,2014,32(8):760-772.
[36]	Xu Z,Gao Y,Hao Y,et al.Application of a microfluidic chip-based 3D co-culture to test drug sensitivity for individualized treatment of lung cancer[J].Biomaterials,2013,34(16):4109-4117.
[37]	Akay M,Hite J,Avci NG,et al.Drug Screening of Human GBM Spheroids in Brain Cancer Chip[J].Sci Rep,2018,8(1):15423.
[38]	徐鑫,国林义,徐涛,等.高分子纳米载药体系膀胱灌注治疗在原位膀胱癌动物模型中的初步应用[J].临床泌尿外科杂志,2019,34(11):895-900.
[39]	Lunardi A,Pandolfi PP.A co-clinical platform to accelerate cancer treatment optimization[J].Trends Mol Med,2015,21(1):1-5.
[40]	Byrne AT,Alferez DG,Amant F,et al.Interrogating open issues in cancer precision medicine with patientderived xenografts[J].Nat Rev Cancer,2017,17(4):254-268.
[41]	Kersten K,de Visser KE,van Miltenburg MH,et al.Genetically engineered mouse models in oncology research and cancer medicine[J].EMBO Mol Med,2017,9(2):137-153.
[42]	Lunardi A,Ala U,Epping MT,et al.A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer[J].Nat Genet,2013,45(7):747-755.
[43]	Chen Z,Akbay E,Mikse O,et al.Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance[J].Clin Cancer Res,2014,20(5):1204-1211.
[44]	Aparicio S,Hidalgo M,Kung AL.Examining the utility of patient-derived xenograft mouse models[J].Nat Rev Cancer,2015,15(5):311-316.
[45]	Zitvogel L,Pitt JM,Daillere R,et al.Mouse models in oncoimmunology[J].Nat Rev Cancer,2016,16(12):759-773.
[46]	Zhang X,Claerhout S,Prat A,et al.A renewable tissue resource of phenotypically stable,biologically and ethnically diverse,patient-derived human breast cancer xenograft models[J].Cancer Res,2013,73(15):4885-4897.
[47]	Garrido-Laguna I,Uson M,Rajeshkumar NV,et al.Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer[J].Clin Cancer Res,2011,17(17):5793-5800.
[48]	Bertotti A,Migliardi G,Galimi F,et al.A molecularly annotated platform of patient-derived xenografts("xenopatients")identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer[J].Cancer Discov,2011,1(6):508-523.
[49]	Fiebig HH,Neumann HA,Henss H,et al.Development of three human small cell lung cancer models in nude mice[J].Recent Results Cancer Res,1985,97:77-86.
[50]	Pan CX,Zhang H,Tepper CG,et al.Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy[J].PLoS One,2015,10(8):e0134346.
[51]	Jager W,Xue H,Hayashi T,et al.Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies[J].Oncotarget,2015,6(25):21522-21532.
[52]	Villarroel MC,Rajeshkumar NV,Garrido-Laguna I,et al.Personalizing cancer treatment in the age of global genomic analyses:PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer[J].Mol Cancer Ther,2011,10(1):3-8.
[53]	Zhan M,Yang RM,Wang H,et al.Guided chemotherapy based on patient-derived mini-xenograft models improves survival of gallbladder carcinoma patients[J].Cancer Commun(Lond),2018,38(1):48.
[54]	Zhao P,Chen H,Wen D,et al.Personalized treatment based on mini patient-derived xenografts and WES/RNA sequencing in a patient with metastatic duodenal adenocarcinoma[J].Cancer Commun(Lond),2018,38(1):54.
[55]	周洁,曾甫清.原位膀胱肿瘤实验动物模型研究进展[J].临床泌尿外科杂志,2004,19(1):56-58.
[56]	Oliveira PA,Gil da Costa RM,Vasconcelos-Nobrega C,et al.Challenges with in vitro and in vivo experimental models of urinary bladder cancer for novel drug discovery[J].Expert Opin Drug Discov,2016,11(6):599-607.
[57]	张廷继,陈一戎,王志平,等.顺铂诱导原代培养人膀胱癌细胞的凋亡[J].中国癌症杂志,2001,11(1):47-49.
[58]	Nickerson ML,Witte N,Im KM,et al.Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response[J].Oncogene,2017,36(1):35-46.
[59]	Bernardo C,Santos LL.Patient-Derived Bladder Cancer Xenografts[J].MethodsMol Biol,2018,1655:169-175.
[60]	Zeng SX,Zhu Y,Ma AH,et al.The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer[J].Clin Cancer Res,2017,23(21):6580-6591.
[61]	Gong Z,Xu H,Su Y,et al.Establishment of a Novel Bladder Cancer Xenograft Model in Humanized Immunodeficient Mice[J].Cell Physiol Biochem,2015,37(4):1355-1368.
[62]	Wang M,Yao LC,Cheng M,et al.Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy[J].Faseb J,2018,32(3):1537-1549.
[63]	Puzio-Kuter AM,Castillo-Martin M,Kinkade CW,et al.Inactivation of p53 and Pten promotes invasive bladder cancer[J].Genes Dev,2009,23(6):675-680.
[64]	Cancer Genome Atlas Research Network.Comprehensive molecular characterization of urothelial bladder carcinoma[J].Nature,2014,507(7492):315-322.
[65]	Netto GJ,Tafe LJ.Emerging Bladder Cancer Biomarkers and Targets of Therapy[J].Urol Clin North Am,2016,43(1):63-76.
[66]	Mitra AP,Cote RJ.Molecular pathogenesis and diagnostics of bladder cancer[J].Annu Rev Pathol,2009,4:251-285.
[67]	Zhang ZT,Pak J,Shapiro E,et al.Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma[J].Cancer Res,1999,59(14):3512-3517.
[68]	Al-Ahmadie HA,Iyer G,Lee BH,et al.Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer[J].Nat Genet,2016,48(4):356-358.
[69]	Gheibi P,Zeng S,Son KJ,et al.Microchamber Cultures of Bladder Cancer:A Platform for Characterizing Drug Responsiveness and Resistance in PDX and Primary Cancer Cells[J],Sci Rep,2017,7(1):12277.